Another important avenue for future investigation is to find out whether CCL-2 and sFasL specifically reflect a severity of the liver disease, or rather correlate with some other pathophysiological aspects of being obese and insulin resistant, for example, of the systemic inflammation or the co-morbid conditions. Here, FASLG is linked to liver disorder.